A rabbit Langendorff heart proarrhythmia model: Predictive value for clinical identification of Torsades de Pointes

British Journal of Pharmacology

Volumn 149, Issue 7, 2006, Pages 845-860

  Lawrence, C L ^a   Bridgland Taylor, M H ^a   Pollard, C E ^a   Hammond, T G ^a   Valentin, J P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Arrhythmia; Cardiac; Early after depolarisations; Electrophysiology; In vitro; Map; Monophasic action potential; Proarrhythmia; QT prolongation; Torsades de Pointes

Indexed keywords

ALMOKALANT; ASTEMIZOLE; AZIMILIDE; AZITHROMYCIN; BEPRIDIL; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; DESIPRAMINE; DIPHENHYDRAMINE; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; ENCAINIDE; ERYTHROMYCIN; FLECAINIDE; GREPAFLOXACIN; HALOFANTRINE; IBUTILIDE; IMIPRAMINE; KETANSERIN; MIBEFRADIL; NIFEDIPINE; PIMOZIDE; PROCAINAMIDE; SERTINDOLE; SOTALOL; TERFENADINE; TERODILINE; UNINDEXED DRUG;

ACCURACY; AFTERHYPERPOLARIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEART PROARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; IC 50; ISOLATED HEART; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; RABBIT; RISK ASSESSMENT; SCORING SYSTEM; TORSADE DES POINTES;

ANIMALS; ARRHYTHMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART; HUMANS; LONG QT SYNDROME; MEMBRANE POTENTIALS; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; RATS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TIME FACTORS; TORSADES DE POINTES;

EID: 33845194767     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706894     Document Type: Article

References (50)

1. Abi-Gerges N, Small BG, Lawrence CL, Hammond TG, Valentin JP, Pollard CE (2004). Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol 142: 1255-1264.
2. Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding W-G et al. (2005). Cellular and ionic mechanisms for drug-induced Long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 45: 300-307.
3. Andriole VT, Haverstock DC, Choudhri SH (2005). Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Safety 28: 443-452.
4. Anon (2005a). Committee for Proprietary Medicinal Products (CPMP). ICHE14: Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. CPMP/ICH 2/04.
5. Anon (2005b). Committee for Proprietary Medicinal Products (CPMP). ICHS7B: Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. CPMP/ICH 423/02.
6. Antzelevitch C, Shimizu W (2002). Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 17: 43-51.
7. Belardinelli L, Antzelevitch C, Vos M (2003). Assessing predictors of drug-induced Torsade de Pointes. Trends Pharmocol Sci 24: 619-625.
8. Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ et al. (2004). Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109: 990-996.
9. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 3: 599-604.
10. Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY et al. (2005). Prediction of the risk of Torsade de Pointes using the model of isolated canine purkinje fibres. Br J Pharmacol 144: 376-385.
11. Chen F, Esmailian F, Sun W, Wetzel GT, Sarma JS, Singh BN et al. (2002). Azimilide inhibits multiple cardiac potassium currents in human atrial myocytes. Cardiovasc Pharmacol Ther 7: 255-264.
12. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E et al. (2005). QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 46: 792-799.
13. Choudhury L, Grais IM, Passman RS (1999). Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 4: 206-207.
14. Coraboeuf E, Deroubaix E, Escande D, Coulombe A (1988). Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibres. Cardiovasc Res 6: 375-384.
15. Curtis MJ, Walker MJA (1988). Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc Res 22: 656-665.
16. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590-597.
17. + current by the class Ia agent disopyramide in cat ventricular myocytes. J Pharmacol Exp Ther 272: 714-723.
18. Drolet B, Yang T, Daleau P, Roden DM, Turgeon J (2003). Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 41: 934-937.
19. DrugDex® (2005). Drug Knowledges System Thomson Micromedex.
20. Fossa AA, Wisialowski T, Wolfgang E, Wang E, Avery M, Raunig Dl et al. (2004). Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol 486: 209-221.
21. Gintant GA, Limberis JT, Mcdermott JS, Wegner CD, Cox BF (2001). The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacology 37: 607-618.
22. Grace AA, Camm AJ (1998). Quinidine. Drug Ther 338: 35-45.
23. Hondeghem LM (1994). Computer aided development of antiarrhythmic agents with class IIIa properties. J Cardiovasc Electrophysiol 5: 711-721.
24. Hondeghem LM, Carlsson L, Duker G (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
25. Hondeghem LM, Hoffman P (2003). Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse-use dependence and instability. J Cardiovasc Pharmacol 41: 14-24.
26. Hondeghem LM, Lu HR, Van Rossen K, De Clerck F (2003). Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 14: 1-8.
27. Houltz B, Darpo B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJ et al. (1998). Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 5: 1044-1057.
28. Kim SY, Benowitz NL (1990). Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Safety 5: 393-420.
29. Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2005). Nonclinical proarrhythmia models: predicting torsades de pointes. J Pharmacol Toxicol Methods 52: 46-59.
30. Lehmann MH, Hardy S, Archibald D, Quart B, Macneil DJ (1996). Sex difference in risk of torsade de pointes with D,L-sotalol. Circ 94: 2535-2541.
31. Malik M (2005). Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies. Heart Rhythm 2: 773-776.
32. + current in cardiac ventricular myocytes. Am J Physiol 266: H1286-H1299.
33. Matz J (2005). The return of sertindole - postmarketing experience with a compound causing QTc interval prolongation. Safety Pharmacology Society Proceedings Fifth Annual Meeting; Mannheim; Germany.
34. Milberg P, Eckardt L, Bruns H-J, Biertz J, Ramtin S, Reinsch N et al. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 303: 218-225.
35. Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA et al. (2004). Evaluation of vardenafil and sildenafil on cardiac repolarisation. Am J Cardiol 93: 1378-1383.
36. Ohe T, Kurita T, Shimizu W, Emori T, Shimomura K (1992). Induction of TU abnormalities in patients with torsades de pointes. Ann NY Acad Sci 644: 178-186.
37. Oliphant CM, Green GM (2002). Quinolones: a comprehensive review. Am Family Physician 65: 455-464.
38. Redfern WS, Carlsson L, Davis AS, Lynch WG, Mackenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
39. Schattner A, Gindin J, Geltner D (1989). Fatal torsade de pointes following jaundice in a patient treated with disopyramide. Postgraduate Med J 65: 333-334.
40. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS (1993). Diagnostic criteria for the long QT syndrome. An update. Circulation 88: 782-784.
41. Shah RR, Hondeghem LM (2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2: 758-772.
42. Thomsen MB, Matz J, Volders PG, Vos MA (2006). Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther (in press).
43. Thomsen MB, Truin M, Van Opstal JM, Beekman JD, Volders PG, Stengl M et al. (2005). Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol 100: 279-287.
44. Thomsen MB, Volders PA, Stengl M, Spatjens RLHM, Beekman JDM, Bischoff U et al. (2003). Electrophysiological safety of sertindole in dogs with normal and remodelled hearts. J Pharmacol Exp Ther 307: 776-784.
45. Vieweg WVR (2003). New generation antipsychotic drugs and QTC interval prolongation. Prim Care Companion J Clin Psychiatry 5: 205-215.
46. Virag L, Varro A, Papp JG (1998). Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 357: 268-275.
47. + current in the guinea pig heart. Eur J Pharmacol 338: 71-74.
48. Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Disc Dev 5: 116-126.
49. Wonnacott TH, Wonnacott RJ (1977). Introductory Statistics 3rd edn, Wiley & Sons: New York, London, pp 193.
50. Yap YG, Camm AJ (2003). Drug induced QT prolongation and Torsades de pointes. Heart 89: 1363-1372.